Endpoints
Published November 13, 2026 · Updated November 14, 2026
HHS funnels funding and research toward ibogaine and other psychedelics, with Mark Cuban's help
Read the full story at Endpoints
HHS announced ~$25M for psychedelics research, focusing on ibogaine via ARPA-H. Mark Cuban's Cost Plus Drugs and Beond will aid studies.
Surfaced by this Google Alert
- Gray market psychedelics